Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OC-EIEs in Ovarian Cancer
NCT03393962Phase 2Enrolling by invitation
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Dec 2025
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in ovarian cancer, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Safety of OC-EIEs using CTCAE version 4.0 at 6 months. Started Dec 2025; status: enrolling by invitation.
02
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03393962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393962.